<DOC>
	<DOCNO>NCT02254785</DOCNO>
	<brief_summary>The purpose study ass compare clinical benefit rate patient metastatic castrate-resistant prostate cancer poor prognostic factor treat cabazitaxel novel hormonal agent ( abiraterone enzalutamide ) initial therapy , determine treatment active population . Clinical benefit rate define PSA measurable radiological response duration stable disease &gt; equal 12 week , absence indicator progression . There option cross-over onto arm patient progress .</brief_summary>
	<brief_title>Cabazitaxel v Abiraterone Enzalutamide Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<criteria>Histological diagnosis prostate adenocarcinoma . Able willing provide inform consent comply study procedure Age ≥18 Evidence metastatic disease chest , abdominal , pelvic CT scan and/or bone scan within 6 week registration Castration resistant disease define evidence radiological and/or PSA progression despite castrate level testosterone ( serum testosterone &lt; 50 ng/dL ( 1.7 nmol/L ) ) . For PSA progression , must least 2 sequential rise minimum 1week interval . The first PSA value must ≥ 2 . ( Prostate Cancer Working Group 2 ( PCWG2 ) criterion ) Poor prognosis disease define follow : presence liver metastases OR development castrationresistance within 12 month orchiectomy commencement LHRH antagonist/agonist metastatic disease OR presence 4 follow factor : LDH &gt; ULN ECOG Performance status ( PS ) 2 visceral metastatic disease serum albumin less equal 4 g/dL ALP &gt; ULN &lt; 36 month commencement initial androgen deprivation therapy study enrollment ECOG PS 02 . Adequate endorgan function within 14 day registration : Haemoglobin ≥ 90 g/L Neutrophils ≥ 1.5 x 109 /L Platelets ≥ 100 x 109/L AST &lt; 1.5 x ULN ALT &lt; 1.5 x ULN Bilirubin ≤ 1.0 x ULN ( exception Gilbert 's syndrome ) Creatinine ≤ 1.5 x ULN At least 21 day pass since complete radiotherapy ( exception radiotherapy : least 7 day since complete single fraction ≤ 800 cGy restrict field limitedfield radiotherapy nonmarrow bear area extremity orbit ) time randomization . At least 21 day pass since receive investigational agent time registration . At least 21 day pass since major surgery . Neuropathy ≤ grade 1 time registration . Has recover therapyrelated toxicity ≤ grade 2 ( except alopecia , anemia sign symptom androgen deprivation therapy ) time registration . Eligible abiraterone acetate and/or enzalutamide per standard care practice . Histologic evidence small cell/neuroendocrine prostate cancer . Other chemotherapy regimen beyond one prior course docetaxel . Previously receive treatment cabazitaxel . Received prior nextgeneration antiandrogen ( e.g . enzalutamide , ARN509 ) CYP 17 inhibitor ( e.g . abiraterone , TAK700 ) . Other condition , illness , psychiatric condition , laboratory abnormality may increase risk associate administration cabazitaxel , abiraterone enzalutamide , study participation , may interfere interpretation study result judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>poor prognosis</keyword>
	<keyword>castrate-resistant prostate cancer</keyword>
	<keyword>cabazitaxel</keyword>
	<keyword>abiraterone</keyword>
	<keyword>enzalutamide</keyword>
</DOC>